Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Study—Regulatory Filings Underway Across Four Continents

Peer-Reviewed Phase 3 Data Confirms Efficacy Advantage Over Standard Flu Vaccines

Moderna’s investigational seasonal influenza vaccine, mRNA-1010, is making headlines after pivotal Phase 3 clinical results were published in the New England Journal of Medicine. According to the newly released data, mRNA-1010 outperformed a traditional standard-dose flu vaccine in adults aged 50 and older—providing a relative vaccine efficacy (rVE) of 26.6% (95% CI: 16.7%, 35.4%) in the overall study population. Impressively, this efficacy advantage extended across all the flu strains studied and was consistent for individuals aged 65 and above, a key at-risk group.

Data Table: mRNA-1010 Vaccine Efficacy Across Strains

Consistent Performance Across Age Groups and Risk Profiles

The study confirmed that mRNA-1010’s efficacy was robust across different age groups, risk factor profiles, and prior vaccination histories. For participants aged 65 and above—who are often most vulnerable to severe influenza—the vaccine maintained an rVE of 27.4%. According to the Centers for Disease Control (CDC), the 2024-2025 flu season saw more than 545,000 Americans hospitalized for flu-related illness, a 15-year high, underscoring the urgent need for more effective flu prevention strategies.

Regulatory Review in Progress, Approvals Targeted for 2026

With the positive Phase 3 results now peer-reviewed, Moderna’s mRNA-1010 is under regulatory review in the U.S., Europe, Canada, and Australia. The U.S. FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026. Additional regulatory submissions are planned in other countries throughout the year. If approved, mRNA-1010 could play a key role in combating flu seasons that continue to strain healthcare systems globally.

Implications: mRNA Platform Expands Beyond COVID-19

This pivotal data places Moderna at the forefront of expanding mRNA vaccine technology for seasonal influenza—a critical public health challenge. Unlike traditional flu vaccines, mRNA-1010 is designed for faster updates to match circulating viral strains more closely. This adaptability could help reduce the annual disease burden that disrupts lives and drives major healthcare costs.

Final Take: What to Watch Next

With global regulators reviewing the application and a PDUFA date set for next year, all eyes will be on how the mRNA-1010 vaccine shapes up in approval processes and coming flu seasons. For stakeholders, the question isn’t just whether mRNA-1010 secures approval, but whether it ushers in a new era of flexible, high-efficacy flu vaccination strategies poised to tackle the fluctuating challenges of seasonal influenza.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI